Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE3B | Q13370 | 2/20 | 0.51 |
| ▸ | PDE3A | Q14432 | 2/20 | 0.51 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.44 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | PTGER3 | P43115 | 1/20 | 0.43 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.43 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.42 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | KMO | O15229 | 1/20 | 0.42 |
| ▸ | GPR55 | Q9Y2T6 | 1/20 | 0.41 |
| ▸ | PLK1 | P53350 | 1/20 | 0.41 |
| ▸ | HTR1A | P08908 | 1/20 | 0.40 |
| ▸ | DRD2 | P14416 | 1/20 | 0.40 |
| ▸ | HTR2A | P28223 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3331324 | 0.87 | CYP11B2 (0.53) | PDE3BPDE3ACYP11B1CYP11B2ALOX5 | |
| SCHEMBL280110 | 0.81 | TSHR (0.58) | PDE3BPDE3ATSHRHTTALDH1A1 | |
| SCHEMBL9467658 | 0.80 | PDE3B (0.51) | PDE3BPDE3ACYP11B1CYP11B2TSHR | |
| SCHEMBL653919 | 0.80 | PDE3B (0.51) | PDE3BPDE3ACYP11B1CYP11B2TSHR | |
| SCHEMBL30991588 | 0.80 | PDE3B (0.51) | PDE3BPDE3ACYP11B1CYP11B2TSHR | |
| SCHEMBL993713 | 0.80 | PDE3B (0.51) | PDE3BPDE3ACYP11B1CYP11B2TSHR | |
| SCHEMBL13780087 | 0.80 | KMO (0.58) | PDE3BPDE3ATSHRHTTMAPT | |
| SCHEMBL265087 | 0.80 | PDE3B (0.54) | PDE3BPDE3ACYP11B1CYP11B2TSHR | |
| SCHEMBL30336556 | 0.80 | PDE3B (0.54) | PDE3BPDE3ACYP11B1CYP11B2TSHR | |
| SCHEMBL1119881 | 0.80 | PTGER3 (0.51) | PDE3BPDE3ACYP11B1CYP11B2TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170114075-A1 | SPIRO-OXINDOLE COMPOUNDS AND THEIR USE AS THERAPEUTIC AGENTS | XENON PHARMACEUTICALS INC. (CA) | 2017-04-27 | — | — | US | disclosed |
| US-9458178-B2 | Spiro-oxindole compounds and their use as therapeutic agents | XENON PHARMACEUTICALS INC. (CA) | 2016-10-04 | — | — | US | disclosed |
| CN-105218565-A | Spiral shell oxindole compounds and the purposes as therapeutical agent thereof | XENON PHARMACEUTICALS INC | 2016-01-06 | — | — | CN | disclosed |
| CN-105175433-A | Spiro-oxindole compounds and their use as therapeutic agents | XENON PHARMACEUTICALS INC | 2015-12-23 | — | — | CN | disclosed |
| EP-2942350-A1 | SPIRO-OXINDOLE COMPOUNDS AND THEIR USE AS THERAPEUTIC AGENTS | Xenon Pharmaceuticals Inc. (CA) | 2015-11-11 | — | — | EP | disclosed |
| US-20150291623-A1 | SPIRO-OXINDOLE COMPOUNDS AND THEIR USE AS THERAPEUTIC AGENTS | XENON PHARMACEUTICALS INC. (CA) | 2015-10-15 | — | — | US | disclosed |
| EP-2350090-B1 | SPIRO-OXINDOLE COMPOUNDS AND THEIR USE AS THERAPEUTIC AGENTS | XENON PHARMACEUTICALS INC (CA) | 2015-06-03 | — | — | EP | disclosed |
| US-8916580-B2 | Spiro-oxindole compounds and their use as therapeutic agents | XENON PHARMACEUTICALS INC. (CA) | 2014-12-23 | — | — | US | disclosed |
| CN-103664973-A | Spiro-oxindole compounds and their use as therapeutic agents | XENON PHARMACEUTICALS INC | 2014-03-26 | — | — | CN | disclosed |
| US-20130252962-A1 | SPIRO-OXINDOLE COMPOUNDS AND THEIR USE AS THERAPEUTIC AGENTS | XENON PHARMACEUTICALS INC (CA) | 2013-09-26 | — | — | US | disclosed |
| US-8415370-B2 | Spiro-oxindole compounds and their uses as therapeutic agents | XENON PHARMACEUTICALS INC. (CA) | 2013-04-09 | — | — | US | disclosed |
| US-20120295897-A1 | SPIRO-OXINDOLE COMPOUNDS AND THEIR USES AS THERAPEUTIC AGENTS | XENON PHARMACEUTICALS INC. (CA) | 2012-11-22 | — | — | US | disclosed |
| US-8263606-B2 | Spiro-oxindole compounds and their use as therapeutic agents | XENON PHARMACEUTICALS INC. (CA) | 2012-09-11 | — | — | US | disclosed |
| US-20100137299-A1 | SPIRO-OXINDOLE COMPOUNDS AND THEIR USE AS THERAPEUTIC AGENTS | XENON PHARMACEUTICALS INC. (CA) | 2010-06-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170114075-A1 | SPIRO-OXINDOLE COMPOUNDS AND THEIR USE AS THERAPEUTIC AGENTS | TRPV3, TRPV1, TRPC3 | PDE3B 2164/4885PDE3A 1609/4885CYP11B1 419/4885 |
| US-20130252962-A1 | SPIRO-OXINDOLE COMPOUNDS AND THEIR USE AS THERAPEUTIC AGENTS | TRPV3, TRPV1, TRPC3 | PDE3B 2164/4885PDE3A 1609/4885CYP11B1 419/4885 |
| US-20150291623-A1 | SPIRO-OXINDOLE COMPOUNDS AND THEIR USE AS THERAPEUTIC AGENTS | TRPV3, TRPV1, TRPC3 | PDE3B 2164/4885PDE3A 1609/4885CYP11B1 419/4885 |
| US-20120295897-A1 | SPIRO-OXINDOLE COMPOUNDS AND THEIR USES AS THERAPEUTIC AGENTS | TRPV3, TRPC3, TRPV1 | PDE3B 2220/4885PDE3A 1648/4885CYP11B1 433/4885 |
| US-20100137299-A1 | SPIRO-OXINDOLE COMPOUNDS AND THEIR USE AS THERAPEUTIC AGENTS | TRPV3, TRPV1, TRPC3 | PDE3B 2164/4885PDE3A 1609/4885CYP11B1 419/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.